15,615 results match your criteria Annals of the Rheumatic Diseases[Journal]


COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.

Ann Rheum Dis 2020 Jul 6. Epub 2020 Jul 6.

Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218341DOI Listing

Response to: 'Comparative analysis of synovial inflammation after SARS-CoV-2 infection' by Alivernini .

Ann Rheum Dis 2020 Jul 6. Epub 2020 Jul 6.

Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218368DOI Listing

Comparative analysis of synovial inflammation after SARS-CoV-2 infection.

Ann Rheum Dis 2020 Jul 6. Epub 2020 Jul 6.

Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218315DOI Listing

Should patients starting biologics be screened for COVID-19?

Ann Rheum Dis 2020 Jul 6. Epub 2020 Jul 6.

Rheumatology, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218437DOI Listing

Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu .

Ann Rheum Dis 2020 Jul 6. Epub 2020 Jul 6.

Interinstitutional Epidemiology Unit, Azienda Unita Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218364DOI Listing

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.

Ann Rheum Dis 2020 Jul 3. Epub 2020 Jul 3.

Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.

Objectives: To assess the safety and efficacy of interleukin (IL)-6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation.

Methods: We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO/FiO <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels). Sarilumab 400 mg was administered intravenously in addition to standard of care and results were compared with contemporary matched patients treated with standard of care alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218122DOI Listing

Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease.

Ann Rheum Dis 2020 Jul 3. Epub 2020 Jul 3.

Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218032DOI Listing

Response to: 'Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease' by Ruscitti .

Ann Rheum Dis 2020 Jul 3. Epub 2020 Jul 3.

Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218143DOI Listing

Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills .

Ann Rheum Dis 2020 Jul 2. Epub 2020 Jul 2.

Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218263DOI Listing

Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey.

Ann Rheum Dis 2020 Jul 2. Epub 2020 Jul 2.

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217967DOI Listing

Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß .

Ann Rheum Dis 2020 Jul 2. Epub 2020 Jul 2.

Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218069DOI Listing

Methotrexate: what are the true risks of treatment?

Ann Rheum Dis 2020 Jul 1. Epub 2020 Jul 1.

Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217207DOI Listing

Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease-associated macrophage activation syndrome.

Ann Rheum Dis 2020 Jul 1. Epub 2020 Jul 1.

Rheumatology Department, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217917DOI Listing

Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi .

Ann Rheum Dis 2020 Jun 30. Epub 2020 Jun 30.

Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218328DOI Listing

Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis.

Ann Rheum Dis 2020 Jun 30. Epub 2020 Jun 30.

Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218258DOI Listing

Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT.

Ann Rheum Dis 2020 Jun 30. Epub 2020 Jun 30.

Dept Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Objective: To prospectively investigate whether differences in pulmonary vasculature exist in systemic sclerosis (SSc) and how they are distributed in patients with different pulmonary function.

Methods: Seventy-four patients with SSc undergoing chest CT scan for interstitial lung disease (ILD) screening or follow-up were prospectively enrolled. A thorough clinical, laboratory and functional evaluation was performed the same day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217359DOI Listing

Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group.

Ann Rheum Dis 2020 Jun 30. Epub 2020 Jun 30.

Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.

Objectives: To explore whether trial population characteristics modify treatment responses across various interventions, comparators and rheumatic conditions.

Methods: In this meta-epidemiological study, we included trials from systematic reviews available from the Cochrane Musculoskeletal Group published up to 23 April 2019 in Cochrane Library with meta-analyses of five or more randomised controlled trials (RCTs) published from year 2000. From trial reports, we extracted data on 20 population characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217237DOI Listing

Response to: 'Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease' by Akiyama .

Ann Rheum Dis 2020 Jun 26. Epub 2020 Jun 26.

Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of Österreichische Gesundheitskasse (ÖGK) and Research Funds of the Austrian Workers Compensation Board (AUVA),1st Medical Department, Hanusch Hospital, Wien, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218174DOI Listing

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.

Ann Rheum Dis 2020 Jun 26. Epub 2020 Jun 26.

Division of Rheumatology and Clinical Immunology, Deparmtent of Medicine IV, Ludwig Maximilians University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218075DOI Listing

Case of acute arthritis following SARS-CoV-2 infection.

Ann Rheum Dis 2020 Jun 26. Epub 2020 Jun 26.

Department of Pathology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218281DOI Listing

Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Ann Rheum Dis 2020 Jun 26. Epub 2020 Jun 26.

Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217255DOI Listing

Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease.

Ann Rheum Dis 2020 Jun 26. Epub 2020 Jun 26.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218124DOI Listing

Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani .

Ann Rheum Dis 2020 Jun 25. Epub 2020 Jun 25.

Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218179DOI Listing

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.

Ann Rheum Dis 2020 Jun 24. Epub 2020 Jun 24.

Department of Rheumatology, Zurich University Hospital, Zurich, Switzerland

Objective: To compare effectiveness of treatment with secukinumab (SEC) with that of alternative tumour necrosis factor inhibitors (TNFis) in patients with axial spondyloarthritis (axSpA) after withdrawal from one or more TNFis.

Methods: Patients diagnosed as having axSpA in the Swiss Clinical Quality Management cohort were included if they had initiated SEC (n=106) or an alternative TNFi (n=284) after experiencing TNFi failure. Drug retention was investigated with matching weights propensity score (PS) analyses and multiple adjusted Cox proportional hazards models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2019-215934DOI Listing

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.

Ann Rheum Dis 2020 Jun 24. Epub 2020 Jun 24.

University of Cambridge, Cambridge, UK.

Objectives: Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial.

Methods: Patients relapsing with granulomatosis with polyangiitis or microscopic polyangiitis were prospectively enrolled and received remission-induction therapy with rituximab (4×375 mg/m) and a higher or lower dose glucocorticoid regimen, depending on physician choice: reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2019-216863DOI Listing

Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19.

Ann Rheum Dis 2020 Jun 24. Epub 2020 Jun 24.

Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218009DOI Listing

Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak.

Ann Rheum Dis 2020 Jun 24. Epub 2020 Jun 24.

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, New Territories, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218220DOI Listing

Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience.

Ann Rheum Dis 2020 Jun 23. Epub 2020 Jun 23.

Servicio de Reumatología, Universidad Autónoma de Nuevo León, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218198DOI Listing
June 2020
10.377 Impact Factor

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.

Ann Rheum Dis 2020 Jun 22. Epub 2020 Jun 22.

Université de Paris Sud-Saclay, Le Kremlin Bicêtre, France.

Objectives: To evaluate the long-term efficacy and safety of canakinumab to treat patients with colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to 113) of the CLUSTER study.

Methods: Patients received open-label canakinumab 150 or 300 mg, every 4 or 8 weeks during a 72-week period. We evaluated disease activity every 8 weeks using the physician global assessment (PGA) of disease activity, counting the number of flares, and measuring concentrations of C reactive protein (CRP) and serum amyloid A (SAA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217419DOI Listing

Kawasaki disease or Kawasaki syndrome?

Ann Rheum Dis 2020 Jun 22. Epub 2020 Jun 22.

Professor Emeritus, Università degli Studi di Genova, Genoa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335693PMC

Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues.

Ann Rheum Dis 2020 Jun 22. Epub 2020 Jun 22.

Clinical Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran (the Islamic Republic of)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218038DOI Listing

Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.

Ann Rheum Dis 2020 Jun 19. Epub 2020 Jun 19.

Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-218068DOI Listing